Treatment with CD34+ hematopoietic stem/progenitor cells has been shown before to improve functional recovery in non-human models of ischemic stroke via promotion of angiogenesis and neurogenesis. A pilot study undertaken by researchers from Imperial College Healthcare NHS Trust and Imperial College London has now shown promise in rapid treatment of serious strokes. The study, the first of its kind published in the UK, treated patients using stem cells from bone marrow.
According to the Stroke Association, about 152,000 people suffer a stroke in the UK alone each year. However, the five patients treated in the recent Imperial College pilot study all showed improvements. According to doctors, four of those had suffered the most severe kind of stroke, which leaves only four percent of people alive or able to live independently six months after the event. All four of the patients were alive after six months.
A particular set of CD34+ stem cells was used, as they help with the production of blood cells and blood vessels’ lining cells. These same cells have been found to improve the effects of stroke in animals, and they assist in brain tissue and blood growth in the affected areas of the brain. The CD34+ cells were isolated from samples taken from patients’ bone marrow and then infused into the affected area via an artery that leads to the brain, using keyhole surgery.
The innovative stem cell treatment differs from others in one important way: patients are treated within seven days of their stroke, rather than six months hence. The stroke sufferers all recorded improvements in terms of clinical measures of disability, despite four of the five having suffered the most severe kind of stroke.
Autologous CD34+ selected stem/progenitor cell therapy delivered intra-arterially into the infarct territory can be achieved safely in patients with acute ischemic stroke. Future studies that address eligibility criteria, dosage, delivery site, and timing and that use surrogate imaging markers of outcome are desirable before larger scale clinical trials.
Read more here:
A paper detailing the research was published in journal Stem Cells Translational Medicine:
Via Dr. Stefan Gruenwald, Jocelyn Stoller